Cyclacel Pharmaceuticals Inc. (CYCC)

1.60
NASDAQ : Health Technology
Prev Close 1.60
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.47 / 10.90
Avg Volume 570.60K
Exchange NASDAQ
Shares Outstanding 11.90M
Market Cap 19.29M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock Goes Ex-Dividend Soon

On 1/11/18, Cyclacel Pharmaceuticals Inc's 6% Convertible Exchangeable Preferred Stock will trade ex-dividend, for its quarterly dividend of $0.15, payable on 2/1/18. As a percentage of CYCCP's recent share price of $5.71, this dividend works out to approximately 2.63%, so look for shares of CYCCP to trade 2.63% lower — all else being equal — when CYCCP shares open for trading on 1/11/18.

Cyclacel Reviews 2017 Achievements And Announces Key Business Objectives For 2018

Cyclacel Reviews 2017 Achievements And Announces Key Business Objectives For 2018

Company to Present at the Biotech ShowcaseTM 2018 Conference

Cyclacel Pharmaceuticals' Preferred Stock Crosses Above 8.5% Yield Territory

In trading on Tuesday, shares of Cyclacel Pharmaceuticals Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 8.5% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.55 on the day. As of last close, CYCCP was trading at a 26.00% discount to its liquidation preference amount.

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

- Conference Call Scheduled November 9, 2017 at 4:30 p.m. ET -

Ex-Div Reminder for Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock

On 10/12/17, Cyclacel Pharmaceuticals Inc's 6% Convertible Exchangeable Preferred Stock will trade ex-dividend, for its quarterly dividend of $0.15, payable on 11/1/17. As a percentage of CYCCP's recent share price of $8.75, this dividend works out to approximately 1.71%, so look for shares of CYCCP to trade 1.71% lower — all else being equal — when CYCCP shares open for trading on 10/12/17.

Cyclacel Pharmaceuticals' Preferred Stock Shares Cross 10% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 10% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $5.95 on the day. As of last close, CYCCP was trading at a 37.00% discount to its liquidation preference amount.

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 

Conference Call Scheduled August 9, 2017 at 4:30 p.m. EDT

Cyclacel Announces Selection Of Recommended Phase 2 Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression

Cyclacel Announces Selection Of Recommended Phase 2 Dose For CYC065 And Evidence Of Durable Target Engagement And Mcl-1 Biomarker Suppression

Part 2 of study will focus on cyclin E amplified drug resistant solid tumors

Cash Dividend On The Way From Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock

Cash Dividend On The Way From Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock

On 7/12/17, Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock will trade ex-dividend, for its quarterly dividend of $0.15, payable on 8/1/17. As a percentage of CYCCP's recent share price of $6.69, this dividend works out to approximately 2.24%, so look for shares of CYCCP to trade 2.24% lower — all else being equal — when CYCCP shares open for trading on 7/12/17.

Cyclacel Pharmaceuticals' 6% Preferred Stock Shares Cross 9.5% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9.5% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.25 on the day. This compares to an average yield of 10.60% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

Conference Call Scheduled May 11, 2017 at 4:30 p.m. EDT

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results

Conference Call Scheduled March 28, 2017 at 4:30 p.m. EDT

Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, A Novel Cancer-Specific Mechanism Of Action, In Research Published In JNCI

CYC065 found effective against lung cancer cell lines including those with KRAS mutations

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Also up early Thursday: Bellicum and Novocure.

Cyclacel Pharmaceuticals' Preferred Stock Shares Cross 9% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.58 on the day. This compares to an average yield of 10.81% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.